Edwards Lifesciences (EW) FY2025 10-K Annual Report
Edwards Lifesciences (EW) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 25, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Edwards Lifesciences FY2025 10-K Analysis
Business Overview
- • Structural heart pure-play: TAVR, TMTT, and Surgical segments targeting aortic, mitral, tricuspid, and pulmonic valve disease
- • TMTT fastest-growing segment: revenue share expanded to 9% in FY2025 vs 7% in FY2024 and 4% in FY2023
- • KONECT RESILIA aortic valved conduit launched in Europe in 2025; EARLY TAVR trial 2024 data supporting asymptomatic aortic stenosis indication expansion
- • R&D spend ~18% of 2025 sales, up ~2% YoY; ~16,000 employees worldwide as of December 31, 2025
- • TAVR share of net sales declined to 74% in FY2025 from 77% in FY2023, reflecting deliberate portfolio diversification toward TMTT
Management Discussion & Analysis
- • Revenue $6.07B, up $628.1M (+11.5% YoY); TMTT best-performing segment +56.4% to $550.6M; Surgical weakest at +4.9% to $1.03B
- • Gross profit as % of net sales decreased due to higher operational expenses; litigation expenses surged to $325.4M in 2025 vs $40.4M in 2024; effective tax rate 17.0% vs 9.8%
- • Operating cash flow $1.60B, up $1.05B YoY; capex $260.2M in 2025, guided ~$280M in 2026
- • Share buybacks $884.7M (11.7M shares) in 2025; $2.0B repurchase authority remaining; no dividends mentioned; $600M senior notes due 2028 outstanding
- • Key risks: IRS transfer pricing dispute ($269.3M additional tax claimed), Pillar Two added $19.1M tax expense, and ongoing IP litigation
Risk Factors
- • Section 232 investigation by U.S. Dept. of Commerce into medical device imports could impose tariffs, raising manufacturing costs and disrupting Edwards' supply chain
- • EU MDR compliance risk: unresolved EU-Switzerland Mutual Recognition Agreement may block Edwards from placing devices on EU market via Swiss operations
- • Single-source supplier dependency for key materials; regulatory burden of FDA qualification makes replacement difficult and costly
- • Competitors introducing new TAVR/TMTT technologies competing for same hospital catheterization labs, directly constraining Edwards' procedure volumes
- • GDPR, HIPAA, and CCPA compliance exposure across multiple jurisdictions; GDPR noncompliance penalties and CCPA private right of action create layered financial liability
Edwards Lifesciences FY2025 Key Financial MetricsXBRL
Revenue
$6.1B
▲ +11.5% YoY
Net Income
$1.1B
▼ -74.3% YoY
Gross Margin
78.0%
▼ -144bp YoY
Operating Margin
20.8%
▼ -451bp YoY
Net Margin
17.7%
▼ -5905bp YoY
ROE
10.4%
▼ -3137bp YoY
Total Assets
$13.7B
▲ +4.9% YoY
EPS (Diluted)
$1.83
▼ -73.7% YoY
Operating Cash Flow
$1.6B
▲ +194.2% YoY
Source: XBRL data from Edwards Lifesciences FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Edwards Lifesciences Annual Reports
Get deeper insights on Edwards Lifesciences
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.